Senior Director
Tarsus Pharmaceuticals
Senior Director
Tarsus Pharmaceuticals
Develops FDA-approved ophthalmic therapies
About the Role
The Sr Director, Clinical Sciences will be accountable for the scientific integrity, quality, and strategic impact of eyecare clinical studies from early development through late-stage registration and lifecycle management. This role partners closely with Clinical Operations, Regulatory, Biostats, Medical Affairs, and Commercial to translate target product profiles into robust clinical development plans and high‑quality trial designs.
Let’s talk about some of the key responsibilities of the role:
Factors for Success:
Leadership Competencies - This role requires mastery of the Tarsus Leadership Competencies for Leading Teams, including:
Few Other Details Worth Mentioning:
At Tarsus, we understand the importance of attracting and retaining top talent. The expected base pay range for this position is $255,000 - $357,000 plus bonus, stock equity, and comprehensive benefits. The base pay range reflects the target range for this position, but individual pay will be determined by additional factors such as job-related skills, experience and relevant education or training. Our benefits include health, dental and vision insurance benefits to ensure your well-being. We believe in work-life balance and offer generous paid time off, including vacation, holidays, and personal days. For more details regarding Tarsus benefits, please visit: https://eb.alliant.com/26tarsusbenefitssnapshot.
#LI-Remote
Tarsus Pharmaceuticals, Inc. is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex including sexual orientation and gender identity, national origin, disability, protected Veteran Status, or any other characteristic protected by applicable federal, state, or local law.
Develops FDA-approved ophthalmic therapies
Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY (lotilaner ophthalmic solution 0.25%), an FDA-approved eye drop for Demodex Blepharitis. The product is applied as a medicated eye drop to kill Demodex mites and relieve eyelid inflammation. The company differentiates itself with a focused ocular/infectious-disease portfolio, an FDA-approved therapy, and active partnerships to expand its research and reach. Its goal is to address unmet medical needs, grow its product lineup through commercialization, and pursue new indications in eye care and infectious diseases.
Explore more opportunities at Tarsus Pharmaceuticals